Objective To determine whether specific patterns of [ 18 F]-AV-1451 tau-PET retention are observed in patients with autopsy-proven sporadic Creutzfeldt-Jakob disease (CJD).
The discovery of radiopharmaceutical agents capable of binding hyperphosphorylated tau protein has facilitated quantification and characterization of in vivo tau deposition in individuals with typical 1,2 and atypical Alzheimer disease (AD) dementia, 3, 4 Lewy body diseases, 5 corticobasal syndrome, 6, 7 and frontotemporal dementia associated with select microtubule-associated protein tau mutations. 8, 9 [ 18 F]-AV-1451 (flortaucipir) is reported to demonstrate good specificity for binding insoluble aggregates of paired helical filaments of tau protein-the building blocks of ADassociated neurofibrillary tangles (NFTs), neuropil threads, and dystrophic neurites of amyloid plaques. 10 The tracer demonstrates lower affinity for tau in other non-AD tauopathies. 10 These findings suggest that [
18 F]-AV-1451 may be used to improve the antemortem diagnosis of patients with slowly progressive neurodegenerative dementing diseases. However, it is unknown whether [ 18 F]-AV-1451 PET imaging can be reliably applied to evaluate patients with rapidly progressive dementia (RPD).
Creutzfeldt-Jakob disease (CJD) represents one of the most common causes of RPD. 11, 12 While clinical algorithms and nonspecific diagnostic tests (e.g., diffusion-weighted magnetic resonance brain sequences) may be used to differentiate CJD from other common causes of RPD, disease-specific biomarkers capable of confirming or refuting the suspected diagnosis are needed to increase diagnostic accuracy, and facilitate counseling concerning treatment and prognosis. Accordingly, we sought to determine whether specific patterns of [ 
Methods
Standard protocol approvals, registrations, and patient consents [ 
Clinical assessment
Enrolled individuals were evaluated together with a knowledgeable collateral source by experienced clinicians (G.S.D., R.B., E.S.M., N.G., B.M.A.) using a semistructured interview and detailed neurologic examination. Patients with CJD were admitted to the neurology inpatient service at Barnes-Jewish Hospital (Washington University School of Medicine, St. Louis, MO) between November 2015 and August 2016 for evaluation and management of RPD. Sporadic CJD was diagnosed according to accepted criteria.
14 CSF biomarkers known to correlate with CJD (e.g., total tau, 14-3-3, real-time quaking-induced conversion) 15, 16 were measured in all patients by the National Prion Disease Pathology Surveillance Center (Case Western Reserve University, Cleveland, OH). Additional investigations were ordered at the discretion of treating clinicians, including paraneoplastic autoantibody testing in all patients, and AD biomarker assessment in one patient (ADmark Alzheimer's Evaluation; Athena Diagnostics, Marlborough, MA). All clinical investigations were performed via Clinical Laboratory Improvement Amendments-approved laboratories, in accordance with established criteria. Patients with CJD were followed until death, and brain-only autopsies were completed.
CN persons and participants with very mild AD dementia were prospectively recruited and assessed within the Knight Alzheimer Disease Research Center longitudinal study of memory and aging. All participants with AD dementia presented with typical amnestic symptoms, met National Institute on Aging-Alzheimer's Association diagnostic criteria for AD dementia, 17 and had elevated levels of cerebral β-amyloid (Aβ), as determined by [ 18 F]-AV-45 (florbetapir) PET imaging. 18 CN participants were devoid of cognitive symptoms (CDR 0) and substantial [ 18 F]-AV-45 retention. PET imaging was completed between 2014 and 2016.
Neuroimaging MRI data were acquired on Siemens 3T scanners (Biograph mMR n = 53, Trio n = 3, or Skyra n = 1; Siemens Medical Solutions, Erlangen, Germany). T1-weighted images were acquired using magnetization-prepared rapid-acquisition gradient echo sequences (appendix e-1, http://links.lww. com/WNL/A216). Images underwent cortical and subcortical parcellation using FreeSurfer 5.3 (http://freesurfer.net), 19 yielding 46 unique brain regions, corresponding to the Desikan atlas.
Aβ-PET imaging was performed following administration of a single IV injection of [ 18 F]-AV-45 (7.2-11.3 mCi), with images acquired on a Biograph mMR (n = 48) scanner or Biograph 40 PET/CT (n = 4) (Siemens Medical Solutions). Data from the 50-to 70-minute postinjection window were converted to standardized uptake value ratios (SUVRs) using a cerebellar cortex reference region, and partial volume was corrected using a regional spread function technique. 20, 21 [
18 F]-AV-45 positivity was defined using an SUVR cutoff of 1.22. 22 Previously defined regions of interest were used for processing, and a summary measure of Aβ deposition was generated using an average of the left and right lateral orbitofrontal, medial orbitofrontal, rostral middle frontal, superior frontal, superior temporal, middle temporal, and precuneus regions. 18 At a dedicated visit, tau-PET imaging was performed following a single IV injection of [ 18 F]-AV-1451 (6.8-10.8 mCi). Data were acquired on a Biograph 40 PET/CT (n = 54) or Biograph mMR (n = 3) scanner (Siemens Medical Solutions). CT brain images were obtained from participants scanned on the Biograph mMR permitting CT attenuation correction to be performed uniformly irrespective of scanner modality. Data for the 80-to 100-minute postinjection window were converted to SUVRs, using the cerebellar cortex as a reference, and partial volume corrected using a regional spread function technique. [ 18 F]-AV-1451 retention was summarized using an average of the left and right inferior temporal cortex, amygdala, entorhinal cortex, and lateral occipital cortices. 22 FreeSurfer regions, examined a priori, were selected to reflect CJD-specific regions defined via neuropathology, or those commonly demonstrating restricted diffusion on MRI. SUVRs from CJD-specific regions and regions previously reported to be sensitive to tau pathology in AD 22 were compared across participants. Neuroimaging analysis was performed by study authors (B.G., H.B., S.M.) who were aware of the clinical diagnoses but blinded to the results of paraclinical testing and neuropathologic analyses.
Neuropathology
Neuropathologic analysis of brain tissue from patients with CJD was completed by study authors (R.P., N.C., K.S., C.F., N.S.) who were aware of the clinical diagnoses but blinded to the results of paraclinical testing and neuroimaging analyses. Macroscopic and microscopic analyses were performed according to standard techniques (appendix e-1, http://links. lww.com/WNL/A216), including immunohistochemistry using anti-Aβ (10D5; Eli Lilly, Indianapolis, IN) and antiphosphorylated tau (PHF-1; a gift from Dr. P. Davies, Feinstein Institute for Medical Research, Manhasset, NY) antibodies. A neuropathologic diagnosis of prionopathy was confirmed by the National Prion Disease Pathology Surveillance Center, in accordance with published criteria. 23 When present, AD neuropathologic change (ADNC) and aging-related tau astrogliopathy were assessed using established criteria. [24] [25] [26] [27] [28] Statistical analyses Clinical data were analyzed using SPSS Statistics (version 24.0; IBM Corp., Armonk, NY). Comparisons across participant groups (CJD, CN persons, AD) were performed using the nonparametric Kruskal-Wallis test. Continuous and categorical measures were compared using the Mann-Whitney U test and Fisher exact test, respectively. Statistical significance was defined as p < 0.05 (Bonferroni-corrected for multiple comparisons, when appropriate).
Results
Specific demographic features, details of clinical presentation and disease course, and results of investigations for patients with sporadic CJD are summarized in table 1. All patients with CJD presented with typical clinical symptoms and signs associated with sporadic CJD, including RPD.
14 No patient with CJD had a family history of CJD or risk factors associated with iatrogenic or variant CJD. Real-time quaking-induced conversion testing was consistent with CJD in 4/5 cases (80%). Total tau was elevated >1,500 pg/mL in the CSF of all patients, supporting the clinical diagnosis. Serum was tested for autoantibodies against CNS antigens in all patients, with low titers of voltage-gated P/Q calcium channel antibodies detected in cases C and E (2/5, 40%). Additional antibodies against thyroperoxidase and antinuclear antigens were identified in case C. In both cases, routine CSF analysis was bland (<5 white blood cells/mm 3 patients with CJD compared to CN persons or participants with AD.
All patients with CJD experienced rapid progression of dementia, with death due to CJD occurring within a median of 4.1 months (range, 2.2-6.9) after presentation to hospital. The median interval from [ 18 F]-AV-1451 PET imaging to death was 1 month (range, 0.2-3.3). Neuropathologic analysis was performed in all cases (table 2 and figure 3) . Characteristic spongiform changes, neuronal loss, and astrogliosis were the most prominent microscopic findings, corroborating the primary diagnosis of CJD. ADNC was a frequent but modest comorbidity ("low" ADNC in 4/5 cases [80%]; "intermediate" ADNC in 1 case 24 [20%]). No patient reported cognitive impairment preceding the onset of symptoms attributed to CJD; thus, findings of ADNC were deemed compatible with "preclinical AD." Additional findings included cerebral amyloid angiopathy in 3/5 cases (60%) and aging-related tau astrogliopathy within the mesial temporal lobe and basal forebrain of case E (1/5, 20%).
Discussion
No specific pattern of [ 18 F]-AV-1451 retention was observed in patients with pathologically proven sporadic CJD. This finding is consistent with previous studies confirming that abnormal prion protein (PrP sc ) deposition in sporadic CJD is not a risk factor for AD-or primary age-related tauopathy-like pathology 29 and with neuropathologic findings in patients AD features prominently in the differential diagnoses of patients with RPD who are referred to CJD surveillance centers. 12, 31 While the majority of CJD cases can be diagnosed using clinical algorithms and nonspecific diagnostic tests (e.g., diffusion-weighted magnetic resonance brain sequences), overlap may be observed in presenting symptoms, rates of progression, and clinical signs. 31 Likewise, although the detection of marked elevations in CSF total-tau levels increases the likelihood of a CJD diagnosis, 15 lower total-tau levels may be reported in patients with specific CJD molecular subtypes (e.g., MM-2, MV-2), 32 while higher levels may be measured in patients with rapidly progressive AD. 33 In addition, elevations in phosphorylated tau may be found in the CSF of patients with CJD (beyond that expected in cognitively normal [CN] persons), 34, 35 impeding the interpretation of CSF tau measures in patients with RPD. Adding to the complexity, the high prevalence of AD in the elderly 36 increases the likelihood that ADNC may be incidentally detected in older patients with RPD attributable to other causes, confounding interpretation of AD-specific biomarkers (i.e., Aβ-PET, and CSF Aβ and phosphorylated tau). Indeed, ADNC was identified in all patients with CJD in this study, and AD-specific CSF biomarkers were consistent with the preclinical stage of AD in the one patient (case A) in whom they were measured (i.e., low Aβ, normal phosphorylated tau). In vivo imaging of tau pathology has the potential to quantify the distribution and density of AD-associated tauopathy. In this way, tau-PET imaging may be used to distinguish patients with RPD attributable to AD from those with a more modest NFT burden, in whom AD is unlikely to account for the clinical presentation. This information may be even more helpful when interpreted together with other AD-and CJD-specific CSF biomarkers. 34, 37 Recruitment of patients with RPD for specialized imaging studies presents numerous challenges, including the need to identify, characterize, and consent patients in a timely fashion, and the need to obtain investigations and maintain follow-up in patients with rapidly declining cognition and function. Nevertheless, imaging was completed according to established protocols in consecutively recruited CJD patients with very mild (CDR 0.5) to severe (CDR 3) dementia. All patients tolerated a minimal scan time of 20 minutes, affirming the tolerability of [ . AD summary values were computed using an average of AD-specific regions of interest, including the left and right inferior temporal cortex, amygdala, entorhinal cortex, and lateral occipital cortices. 22 CJD-specific regions of interest included areas commonly involved on neuropathology: the lateral occipital, caudal middle frontal, superior temporal, fusiform and pericalcarine cortices, and the thalami. AD = Alzheimer disease; CJD = CreutzfeldtJakob disease; CN = cognitively normal; SUVR = standardized uptake ratio value ratio. An obvious advantage of the enrollment of patients with a universally fatal and rapidly progressive disease is the potential for a remarkably brief imaging-to-autopsy interval. Such a brief interval may allow detailed radiologic-pathologic correlations to be investigated under physiologic conditions, circumventing the theoretical limitations associated with autoradiographic studies using postmortem tissue. In vivo [
18 F]-AV-1451 PET retention patterns have previously been shown to recapitulate Braak histopathologic stages in individuals with and without symptomatic AD. 38 However, this finding (in vivo) has yet to be corroborated with neuropathology. Although regional increases in [ Abbreviations: ADNC = Alzheimer disease neuropathologic change; AH = Ammon's horn; ARTAG = aging-related tau astrogliopathy; CA4/CA1 = cornu ammonis areas 4 and 1; CAA = cerebral amyloid angiopathy; CJD = Creutzfeldt-Jakob disease; DN = dentate nucleus; Gr = granular layer; Mol = molecular layer; MTL = mesial temporal lobe; NFT = neurofibrillary tangle; PHG = parahippocampal gyrus; WM = white matter. 1 = rare/minimal; 2 = sparse/mild; 3 = moderate; 4 = frequent/severe; all histologic samples are from the right hemibrain. a Case E also had mild ARTAG in the MTL and basal forebrain 28 and a rare ballooned neuron in the MTL (compatible with VV1 subtype of CJD). ]-AV-1451 PET imaging may be especially useful in the evaluation of patients with more slowly progressive variants of prion disease (e.g., variably proteasesensitive prionopathy 39 and specific subtypes of familial CJD 40 ), in whom the absence of restricted diffusion and predominance of cortical atrophy may mimic findings in AD dementia.
In conclusion, increased [ 18 F]-AV-1451 retention was not observed in patients with RPD due to sporadic CJD. Our results contribute to the emerging understanding that [
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